All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
9 results for "lymphoma"
An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Protocol No
VMONCOLOGY-VMO-01C
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-cell Lymphoma
Split-Dose R-CHOP for Older Adults with DLBCL
Protocol No
WON-SHAH-UW18131-SPLIT-RCHOP
Sub Category
COH-18157-HL: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
PET CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab and RT Free Management in cHL
Protocol No
COH-18157-HL
Sub Category
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Loncastuximab Tesirine with Rituximab vs Immunochemotherapy in DLBCL
Protocol No
ADCT-402-311-DLBCL
Sub Category
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Naïve Mantle Cell Lymphoma
Patients with Previously Treated BTK Naïve Mantle Cell Lymphoma
Protocol No
LOXO-BTK-20019
Sub Category
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination with Rituximab in Subjects with Treatment Naïve Marginal Zone Lymphoma
Ibrutinib With Rituximab in Untreated Marginal Zone Lymphoma
Protocol No
MSKCC-19-243-MZL
Sub Category
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Compl
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Protocol No
ECOG-EA4151
Sub Category